BofA Global Research raises Revolution Medicines price objective to $274 from $264
RVMD•BofA Global Research raised its price objective for Revolution Medicines to $274 from $264.
Related News
Deutsche Telekom says investors already pricing in SpaceX wireless threat
TMUS•
Bioxytran secures free sale certificate for A-SUQAR ahead of UAE market entry
BIXT•
Edwards Lifesciences target price raised to $112 from $101 by Leerink Partners
EW•
Joby Aviation: Needham cuts target price to $10 from $15
JOBY•
HUYA caps awards under amended share incentive plan at 31,749,372 shares
HUYA•